A double-blind phase II trial compared zalcitabine (0.03 mg/kg/day) in combination with zidovudine (720 mg/m 2 /day) and zidovudine monotherapy in 250 clinically stable, previously zidovudinetreated, human immunodeficiency virus -infected children. The combination was well-tolerated except for an increased incidence of neutropenia (14%) compared with that in children receiving monotherapy (5%). No differences were noted for time to first AIDS-defining illness or death, neuropsychologic status, or weight Z scores. In patients in the combination arm, the CD4 cell count decline was slower (13% per year) than in patients receiving monotherapy (25% per year) (P Å .03), and quantitative peripheral blood mononuclear cell virus load remained lower at all time points (P Å .08). Deaths were fewer in patients receiving combination therapy (4) compared with those in patients receiving monotherapy (10) (P Å .083). Thus, administration of zidovudine with zalcitabine to children with prior zidovudine treatment did not result in a significant increase in toxicity compared with that resulting from zidovudine monotherapy and demonstrated improvement in immunologic and virologic surrogate markers.
Antiretroviral therapy with zidovudine has been shown to dine susceptibility [4, 5] . Another major limitation of zidovudine has been its hematologic toxicity, which requires frequent produce improvement in neurodevelopmental deficits, weight monitoring and dose modifications. gain, and CD4 cell numbers in children with human immunodeAlternative approaches for primary treatment of HIV infecficiency virus (HIV) infection [1, 2] . Until recently, zidovudine tion involving combinations of antiretroviral drugs are curhas been the standard first-line drug recommended for initiating rently being explored, with the goal of minimizing drug toxiciantiretroviral therapy in children. The beneficial effects of zidoties and maximizing antiretroviral activities. AIDS Clinical vudine, however, are time-limited because of frequent emerTrials Group (ACTG) protocol 152, a study to evaluate zidogence of viral resistance to the drug [3] . Children receiving vudine in combination with didanosine in symptomatic, prezidovudine monotherapy whose HIV isolates developed in vitro viously untreated HIV-infected children, showed that both diresistance to zidovudine showed greater clinical deterioration danosine monotherapy and zidovudine plus didanosine compared with children whose virus isolates retained zidovucombination therapy had better safety and efficacy than did zidovudine monotherapy and did not significantly differ from each other [6] . The present study was not an efficacy study Received 6 June 1996; revised 18 October 1996. and was designed to evaluate zidovudine in combination with
Informed consent was obtained from parents or guardians. Human experizalcitabine (dideoxycytidine) in clinically stable children who mentation guidelines of the US Department of Health and Human Services and those of the investigators' institutions were followed in the conduct of had previously been treated with zidovudine. Zalcitabine, a this clinical research.
nucleoside analogue reverse transcriptase inhibitor, is highly additive, synergistic, or both effects in vitro when tested in JID 1997; 175 (May) nous pentamidine was permitted on a case-by-case basis with freadults [9, 10] and a subset of those previously treated for quent monitoring of serum amylase concentrations. Use of drugs §6 months [11] . A more recent study [10] indicated that the with potential to cause nephrotoxicity, hepatotoxicity, bone marsustained decline in plasma HIV RNA copies was best achieved row toxicity, or peripheral neuropathy were not permitted, except with a zidovudine plus zalcitabine combination rather than with under circumstances requiring approval by the study chair. Antireteither zidovudine monotherapy or zidovudine plus didanosine.
roviral agents other than zidovudine were not permitted within 6
These studies suggest that the combination of zidovudine and weeks of start of treatment. Abnormal clinical events and laborazalcitabine may be useful for treating HIV-infected adults, partory values were graded from 1 to 4 for management of toxicities ticularly those who have not received previous antiretroviral
arising from the use of study medications.
therapy.
In children, experience with use of zalcitabine has been limited. In an earlier pilot study, zalcitabine was found to be safe
Treatment Protocol
but was not associated with significant antiretroviral activity Children were assigned in double-blind fashion to receive either [12] . A phase II study of monotherapy in children with ad- with the combination of zidovudine plus zalcitabine and was child was evaluated by medical history and physical examinations performed in zidovudine-exposed children.
before, at the time of protocol entry, and every 28 days thereafter. At these visits, subjects were evaluated for intercurrent illness, medications, and hospitalizations. Blood was drawn for complete Methods blood cell count, chemistry determinations, and periodic immunologic and virologic evaluations. Neurologic evaluation was perStudy Design and Entry Criteria formed at enrollment and every 8 weeks subsequently. Routine ACTG 190 was a randomized, double-blind study of zidovudine testing for nerve conduction velocity for children 3-36 months of monotherapy versus a combination of zidovudine and zalcitabine age was optional by site but was strongly recommended for all in HIV-infected children and was conducted at 50 clinical centers children who developed clinical signs or symptoms of peripheral across the United States and Puerto Rico. Children between 3 neuropathy during the study. Chest radiograph, computed tomogramonths and 12 years of age who had laboratory-confirmed HIV phy or magnetic resonance imaging of the brain, retinal examinainfection and whose condition had remained stable while the child tion, and echocardiogram were obtained at study enrollment and received a zidovudine dose of §120 mg/m 2 every 6 h or 480 at the end of the study. Neuropsychologic evaluation was done at mg/m 2 /day for ú6 weeks were eligible for the study. The study entry and at end of study for all children and during the study at patients were stratified at entry according to whether the duration 16-week intervals for children aged 3-30 months and every 32 of prior zidovudine therapy was £52 or ú52 weeks.
weeks for children aged ú30 months. The battery of neuropsychoChildren were excluded if they had history of intolerance to logic tests administered depended on the age of the child. For this zidovudine or toxicity resulting from zidovudine or of disease report we have restricted analysis to the mental index for the progression while being treated with zidovudine. Other exclusion Bayley scales of infant development (age 3-30 months) [14] , the criteria included allergy to zalcitabine, intractable vomiting attribgeneral cognitive index for the McCarthy scales of children's abiliuted to zidovudine, or laboratory abnormalities within 2 weeks ties (age 30 months to 6 years) [15] , and the full-scaled score for before enrollment consisting of total bilirubin ú3 times the upper the Wechsler intelligence score for children-revised (age 6-16 limit of normal, serum aspartate aminotransferase concentration years) [16] . ú10 times the upper limit of normal, serum creatinine ú1. 5 Population pharmacokinetic studies were done for all children. mg/dL, white blood cell count of õ1500 cells/mm 3 , absolute neuThe first 10 children in each arm had timed pharmacokinetic studtrophil count of õ750 cells/mm 3 , hematocrit õ24% (or hemogloies after supervised drug administration. bin õ8 g/dL), and pancreatic amylase ú2 times the upper limit of normal. Children were excluded if they had clinical myositis, history of symptomatic pancreatitis, peripheral neuropathy, abnorDefinition of Primary and Secondary Outcomes mal nerve conduction velocity, presence of cardiomyopathy, or active malignancy requiring chemotherapy.
The primary objectives of the study were to determine pharmacokinetics, safety, and tolerance of zidovudine and zalcitabine Pubertal females were required to undergo a serum test to exclude pregnancy. Treatment with intravenous or intramuscular imwhen given in combination to clinically stable, zidovudine-treated children. Secondary objectives were to compare the two treatment munoglobulin, hyperalimentation, dietary supplements, and hematopoietic agents including granulocyte colony-stimulating factor arms for effect on disease progression as determined by clinical, virologic, and immunologic determinations. The sample size of or erythropoietin were permitted. Age-appropriate immunizations and Pneumocystis carinii pneumonia prophylaxis, given in accorthis study was not intended to have adequate power to compare efficacy of the two treatment arms and had an 80% chance of dance with the then current US Public Health Service guidelines [13] , were strongly recommended in all children. Use of intravedetecting a §4-fold decrease in the clinical event rate. Such a decrease in event rate was not expected to occur in this stable Statistical Methods patient population.
Baseline characteristics were compared between treatment arms Pharmacokinetic methods. Collection of samples for pharmausing the Wilcoxon rank sum test for nongrouped variables and cokinetic studies was blinded to study treatment assignment. Popux 2 tests for grouped variables. The comparison of the time to level lation pharmacokinetic studies were performed for all children, by 3 or 4 toxicity by treatment was the primary statistical analysis. collecting a timed blood sample at study weeks 8, 12, and 32 and Cox models were used to compare the time to level 3 or 4 toxicity 3 samples at study termination. More intensive pharmacokinetic by treatment controlling for baseline (log) CD4 cell count [22] . evaluation was performed for the first 10 children in each treatment
The frequency of severe and life-threatening toxicity was comarm. In these patients, 3 additional samples were collected 0.5-1, pared using an exact Kruskal-Wallis test [23] . Time to event vari-1.5-2.5, and 3-4 h after a supervised dose at study entry and ables, including time to disease progression and time to level 3 or week 4. Observed peak values were assessed only for patients for 4 toxicities, were compared between treatments using the log-rank whom three drug level measurements were obtained after a dose.
test. Longitudinal changes in CD4 cell counts were analyzed using Population pharmacokinetic parameters were estimated using a mixed model analysis of variance for this analysis [24] ; CD4 NONMEM (version IV; NONMEM Project Group, University of cell counts were transformed by use of the logarithm, and the California, San Francisco) and a one-compartment model. Populatransformed value was used as the dependent variable. We assumed tion area under the curve (AUC) was determined by dividing the that the log CD4 cell count for each patient had a linear trajectory dose by the apparent population clearance. The average concentrawith a random intercept and slope. We also assumed that the mean tion was determined by dividing the AUC by the dose interval.
intercept and the mean slope depended on the treatment. Thus, the Serum concentrations for both zidovudine and zalcitabine were fixed effects in the model were treatment (intercept), time (mean determined by RIA [17, 18] . slope), and time 1 treatment (difference in mean slopes by treatSafety and tolerance. For assessing laboratory toxicity, hemament) and baseline age (in years). The random effect was patient, tology and chemistry values were graded in levels from 0 to 4. and time 1 patient. We also tested for an interaction between time, These levels were used for all analyses of laboratory-measured treatment, and prior zidovudine use. Changes in log CD4 cell parameters and were equivalent to the grades used for adverse counts are interpreted as percentage of change, which they closely experiences reporting requirements in most cases. For hemoglobin, approximate. Since changes in weight and neuropsychologic meaneutrophils, aspartate aminotransferase, bilirubin, total amylase, sures over time were not linear, they were analyzed using a Weilipase, blood urea nitrogen, and creatinine, the levels corresponded Johnson test [25] . Weights were transformed into an age-standardto those used for dose modification purposes in this study. Time ized Z score using Epi Info, version 5 (CDC, Atlanta). The effects to first level 3 or 4 toxicity was evaluated. Baseline abnormalities of stratification factors on weight changes were analyzed similarly. that persisted during follow-up were not counted as drug-related toxicities. Patients who progressed from level 3 at baseline to level 4 at follow-up, and patients who for the first time developed a level 3 or 4 toxicity after treatment dispensation, were counted as
Results

new toxicities.
Disease progression. Clinical criteria of disease progression Study Population were development of an opportunistic infection, failure to thrive, neuropsychologic or neurologic deterioration (or both), or death.
A total of 250 patients were enrolled between 4 December Failure to thrive was defined as failure to gain weight at a weight combination therapy had a median CD4 cell count of / 9d27$$my14 03-24-97 13:54:16 jinfa UC: J Infect Toxicities 698/mm 3 , whereas patients receiving zidovudine monotherapy had a median CD4 cell count of 607/mm 3 (P Å .03). Treatment groups showed no difference in time to first biochemical or hematologic toxicity (any) (P Å .47). The percentage of patients who experienced biochemical or hematologic Pharmacokinetic Results toxicities of levels 3 and 4 were, respectively, 0.12 and 0.07 for patients receiving zidovudine and 0.12 and 0.1 for patients Overall, 1034 measurements of zidovudine and 518 of zalcitabine serum levels are included in this evaluation. The mean receiving the combination. Table 2 summarizes results for all patients who developed level 3 or 4 toxicities after treatment peak concentration for zalcitabine was 0.027 { 0.020 mmol/L and occurred most frequently (56%) at the collection time dispensation. There was no significant difference between treatment groups in the time to first level 3 or 4 biochemical toxicity of 1.5 -2.5 h after dosing. The zidovudine peak concentration averaged 7.18 { 3.93 mmol/L and occurred most freafter treatment dispensation (P Å .22). However, there was a significant difference between treatment groups in time to first quently (90%) at the collection time of 0.5 -1 h after dosing. The population AUCs for zalcitabine and zidovudine were hematologic toxicity (P Å .049); this was largely due to more frequent development of neutropenia in patients receiving com-0.11 { 0.04 mmol/h/L and 13.3 { 5.4 mmol/h/L, respectively. Zidovudine levels were similar in the treatment groups, sugbination therapy. Eighteen patients receiving combination therapy and 5 receiving monotherapy experienced level 3 or 4 gesting that zalcitabine did not alter zidovudine pharmacokinetics. Age did not appear to affect the pharmacokinetics of zidoneutropenia. The difference in time to development of neutropenia was also significant (P Å .008) and remained significant vudine or zalcitabine once the child's weight or body surface area had been taken into account. For patients with more inten-(P Å .006) when controlling for whether or not the patient was receiving trimethoprim-sulfamethoxazole, a drug known to be sive pharmacokinetic evaluation, peak zalcitabine levels at week 4 were 1.02 times the levels seen after the first study dose, associated with bone marrow suppression and neutropenia. The time to first grade 3 or 4 clinical toxicities was not significantly demonstrating no significant drug accumulation with repeated doses. Population pharmacokinetic analysis also indicated that different between treatments (P Å .59). The percentages of patients experiencing level 3 or 4 clinical toxicities in the zidozalcitabine apparent clearance (and AUC) were similar after the first and multiple doses.
vudine arm were 0.14 and 0.03 and in the combination arm / 9d27$$my14 03-24-97 13:54:16 jinfa UC: J Infect showed fatty infiltration without active hepatitis.
Alanine aminotransferase (ú10 ULN) 0 2
The 2 children who had baseline cardiac involvement on [26] , a total of 9 patients (3 receiving zidovudine plus zalcitabine and 6 receiving zidovudine) had a new and serious opportunistic infection (table 4). The time to first serious opportunistic infection or death is shown in figure  1 , and the log-rank test indicates no significant difference between treatment arms (13 vs. 7 events, P Å .16).
Physical growth. For this report, the analysis of physical growth and development was focused only on weight data. Figure 2 shows mean change in weight Z score from baseline by treatment. There was no significant difference (Wei-Johnson, P Å .61). There was an appearance of improved weight Z score in patients in the combination arm after week 64 of therapy, but the numbers are too small to make definitive conclusions. The decrease in sample sizes in the later weeks is mostly due to differences in dates of patient entry into the study.
Neurodevelopmental status. A total of 237 patients had valid neuropsychologic assessment at baseline. The Bayley scaled mental index and the McCarthy cognitive scaled index are directly comparable, and hence these cohorts of patients were pooled together. There was not a significant difference between changes in the Bayley mental index and (P Å .41). The children enrolled in the study showed remarkable stability in neurodevelopmental status, and no child met the study end point on the basis of decline in Laboratory Markers for Disease Progression developmental scores.
For study of drug activity, the following parameters were examined: CD4 cell count, serum p24 antigen level, and quantitative viral cultures in PBMC.
CD4 cell count. Figure 3 shows change in mean log CD4 decline in CD4 cell counts was significantly slower in patients Treatment randomized to zidovudine plus zalcitabine compared with the rate of decline in those randomized to zidovudine (P Å .03).
Zidovudine plus
The parameters used to estimate this decline can be interpreted zidovudine therapy of ú6 weeks but £52 weeks versus cell counts was 34.8% for patients receiving zidovudine and 10.2% for patients receiving combination therapy, while for ú52 weeks.
The results of virologic data showed that while log 10 IUPM patients in the ú52-weeks stratum, the rates were 19.5% and 14.6%, respectively. This interaction between prior zidovudine at study entry was similar in patients in the combination therapy and the monotherapy arms, a greater decline was observed in use and the effect of treatment was significant (P Å .011). patients in the combination therapy arm (figure 4). At all time points, the virus load was lower in patients in the combination Discussion therapy arm, although statistical significance was not achieved (Wei-Johnson test for change in log 10 IUPM over time by This is the first study to evaluate safety and toxicity of treatment arm, P Å .08). There was no difference in virologic zalcitabine given in combination with zidovudine in HIVresponse to combination therapy on the basis of length of prior infected children. The results indicate that the combination of zidovudine therapy. zidovudine and zalcitabine is safe and lacking in significant toxicity. In comparison to zidovudine monotherapy, the combination therapy was associated with a significant slowing in
Duration of Prior Zidovudine Treatment
CD4 cell decline. It should be noted, however, that patients receiving combination therapy had slightly but significantly The mixed model approach was used to test whether the stratification factor of duration of prior zidovudine treatment higher baseline CD4 cell counts. Although unlikely, the possibility exists that this difference influenced the slope of CD4 (£52 or ú52 weeks) affected the results. This effect (time 1 treatment 1 stratification factor) was significant for mean log cell decline. The study population had been previously treated with zidovudine for variable periods. The effect of study therchanges in CD4 cell counts but not for weight Z score. Among patients in the £52-weeks stratum, the yearly decrease in CD4 apy on the decline in CD4 cell count was better in the group / 9d27$$my14 03-24-97 13:54:16 jinfa UC: J Infect who were receiving combination therapy and who had £52 Zidovudine in the present study was used at a relatively high dose (720 mg/m 2 /day) administered three times daily; this weeks of prior zidovudine therapy. The CD4 cell counts in the two treatment arms, when analyzed on the basis of duration of dosage was based on several adult studies that have shown treatment effect on p24 antigen levels and CD4 cell counts prior antiretroviral therapies at baseline, were not significantly different. Collectively, the findings suggest that combination with thrice-daily dosing. The observed peak concentrations of zidovudine were somewhat lower than expected [30] , but this treatment was associated with a treatment benefit in terms of CD4 cell decline.
could have resulted from infrequent sampling, such that possibly the ''true'' peak value was missed. The mean population In the present study, the peak levels of zidovudine and zalcitabine were greater than the levels associated with in vitro AUC of zidovudine was close to the predicted value [30] , suggesting that the change in the dose regimen did not affect HIV-1 suppression [27] . Results from this preliminary analysis of population pharmacokinetics for zalcitabine are consistent zidovudine pharmacokinetics. Simulation with the mean pharmacokinetic parameters indicated that switching dosing from with data from previous studies in children [12, 28] . The observed mean peak concentration of 0.027 mmol/L was lower every 6 to every 8 h increased the percentage of time zidovudine levels were below 1 mmol/L from Ç30% to 40%. The than the concentration of 0.056 mmol/L expected on the basis of previous published data [12] but was higher than that (0.022 low frequency (õ5%) of multiple nondetectable drug level measurements in individual patients suggests that the patients mmol/L) reported by Chadwick et al. [28] . Population AUC for zalcitabine was somewhat higher than previously reported were compliant with their drug regimens. A major goal in developing combination therapies is to rein children but lower than that in adults [12, 28, 29] . These differences likely stem from differences in study design and duce toxicity associated with each drug and to improve antiretroviral activity. Zidovudine and zalcitabine each have distinct pharmacokinetic methodologies.
/ 9d27$$my14
03-24-97 13:54:16 jinfa UC: J Infect toxicity profiles and clearance mechanisms. Unlike zidovudine, was not different in any of the treatment groups of zidovudine, zalcitabine, or zidovudine plus zalcitabine, although moderate which is glucuronidated by the liver and kidneys, zalcitabine is cleared mainly by the kidneys, with 75% of the parent drug or worse neuropathy was more commonly seen in patients receiving zalcitabine [11] . We conclude that at the dosage of being recovered in the urine obtained [31, 32] . In adults with advanced HIV disease and no prior zidovudine experience, zalcitabine used in this study, the occurrence of clinically significant peripheral neuropathy is infrequent. zalcitabine has been well-tolerated when used in combination with different doses of zidovudine [9] .
Hematologic toxicity has been a major dose-limiting toxicity for zidovudine; however, concurrent use of granulocyte In children, although prior experience has been limited, zalcitabine has not been associated with major toxicities. In adults, colony-stimulating factor has enhanced our ability to treat children with potentially myelosuppressive drugs, including the major dose-limiting toxicity of zalcitabine is a painful sensorimotor peripheral neuropathy; this toxic effect occurs at zidovudine [34] . Zalcitabine has not been shown to be myelosuppressive in previous studies. In the present study, an doses of §0.06 mg/kg/day in adults and is noted at 8 -14 weeks after treatment initiation [33] . In the present study, only 2 increased incidence of neutropenia was noted in patients in the combination arm, although no child was required to have children were diagnosed with peripheral neuropathy (grades 3 and 4); both were receiving the combination of zidovudine study drugs discontinued permanently, and the toxicity could be controlled by temporary suspension of study drugs and and zalcitabine and both recovered after temporary treatment discontinuation in 1 child and dose reduction in the other. The reintroduction at a reduced dose. Other common side effects attributed to zalcitabine include skin rashes and stomatitis, experience with the use of zalcitabine in two other studies in children was similar [12, 12a] . In an adult study similar in but these effects were not seen in any of the children in the present study. design to ours, the frequency of severe peripheral neuropathy JID 1997; 175 (May) One child died of liver failure in the absence of evidence of to achieve statistical significance for virus load reduction may be attributed to the nature of the study population, which was cliniactive hepatitis on histopathologic examination. This child was randomized to zidovudine monotherapy but had not been recally stable and zidovudine-experienced at the start of therapy. This conclusion is supported by the observation made in adult ceiving therapy for 2 weeks at the time of death. These findings are of interest because of reports of HIV-infected adults whose studies that virus load reduction was more pronounced in zidovudine-naive subjects treated with zidovudine plus zalcitabine than condition is relatively stable and who developed sudden severe hepatomegaly and macrovesicular steatosis along with metain zidovudine-experienced patients [38] . The clinical activity of the combination therapy, as judged bolic acidosis [35] . It has been speculated that these findings in adults might be related to antiretroviral therapy, HIV, or by the effect on measures such as the weight Z score or the neurodevelopmental score, showed that there was no difference another as-yet-unidentified agent.
Two children who were randomized to combination therapy in weight (P Å .61) or neurodevelopmental status between patients in either treatment arm. This was not unexpected, as had underlying cardiac disease at entry, with subsequent worsening of their cardiac function during the study; cardiomyopachildren enrolled into the study were carefully chosen as being stable while receiving zidovudine for varying lengths of time, thy was considered to be the immediate cause of death in 1 child. Both children discontinued study drugs with worsening as judged by attainment of optimum weight and neurodevelopmental status. Thus, this was a select group of patients who of cardiac disease, and the child who died had not been receiving therapy for 18 weeks. The role of antiretroviral therapy in were unlikely to manifest significant gains in areas of weight or neurodevelopment. both cases is unclear; the contribution of either drug to the development of cardiac abnormality must remain speculative,
The present study was not designed to examine efficacy. On the basis of end points of survival and opportunistic infections, as the study was not placebo-controlled and the underlying etiology of the cardiac problem was not established. Cardiac the trial would have had to be continued for 5 years (versus 52 weeks) and to have accrued 1000 patients (versus 250 painvolvement in HIV-infected children may result from underlying infection with HIV, another infection, cardiotoxic drugs, or tients in the present study) in order to detect a hazard ratio of 1.7. It is to be noted, however, that even in this limited study, nutritional deficiencies. Zidovudine may cause mitochondrial damage, and skeletal myopathy and has been associated with more deaths occurred in the zidovudine monotherapy arm (10) than in the combination arm (4). The incidence of AIDS-defincardiomyopathy in children [36] . In adults, cardiac dysfunction has been described with the use of zidovudine, didanosine, ing illnesses in patients in the combination arm was also half that in patients in the monotherapy arm, although the difference and zalcitabine [37] , with resolution of abnormalities upon discontinuation of drugs. It is possible that continued zidovuin mortality and AIDS-defining events in patients in the two arms was not statistically significant. dine therapy in these children with some underlying cardiac dysfunction was associated with worsening cardiac disease;
In summary, the combination of zidovudine and zalcitabine was safe and had an acceptable toxicity profile in children who the role of zalcitabine is unclear. In children who develop cardiomyopathy, discontinuation of zidovudine and use of alhad received prior zidovudine therapy. At the dose used, the frequency of occurrence of peripheral neuropathy was low and ternative therapies should be considered.
An important consideration in drug treatment trials is whether could be safely monitored with careful clinical examination. Clinical parameters of growth and neurodevelopmental scores either drug influences the development of resistance to the other drug and what effect it has on virus burden as well as on CD4
were unaffected in this clinically stable population. Even though this trial was not designed to evaluate efficacy, the cell counts. In the present study, the rate of decline in CD4 cell counts of 13% for patients randomized to the zidovudine plus combination therapy was associated with significantly improved stability of CD4 cell counts, fewer deaths, and a trend zalcitabine arm was significantly different from the 25% decline shown for patients randomized to the zidovudine arm (P Å .03).
toward lower virus load. The results of this study show that the combination therapy is safe and lacking significant toxicity The virus load measurement showed that the children receiving combination therapy showed a greater magnitude of decline startregardless of duration of prior zidovudine treatment. These findings suggest that this combination may be more beneficial ing from within the first 10 weeks of therapy. This difference was maintained throughout the treatment course, although it did than zidovudine monotherapy in HIV-infected children. not achieve statistical significance. Since CD4 cell count and virus load are major prognostic indicators in HIV infection, it is reasonable to conclude that combination therapy with zalcitabine
